Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 4/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.49 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286638 | 1.00 | CSNK1E (0.51) | CSNK1EANPEPERAP2LAP3RNPEP | |
| SCHEMBL1057036 | 1.00 | CSNK1E (0.51) | CSNK1EANPEPERAP2LAP3RNPEP | |
| Hydrochloric Acid SCHEMBL5223863 | 0.98 | CSNK1E (0.50) | CSNK1EANPEPERAP2LAP3RNPEP | |
| Hydrochloric Acid SCHEMBL8734228 | 0.98 | CSNK1E (0.50) | CSNK1EANPEPERAP2LAP3RNPEP | |
| SCHEMBL7300383 | 0.92 | CSNK1E (0.54) | CSNK1EANPEPLAP3RNPEPDNPEP | |
| SCHEMBL3358249 | 0.90 | CSNK1E (0.51) | CSNK1EANPEPLAP3RNPEPDNPEP | |
| SCHEMBL6895260 | 0.90 | CSNK1E (0.51) | CSNK1EANPEPLAP3RNPEPDNPEP | |
| Hydrochloric Acid SCHEMBL7310009 | 0.90 | CSNK1E (0.53) | CSNK1EANPEPLAP3RNPEPDNPEP | |
| SCHEMBL4689505 | 0.86 | LAP3 (0.59) | CSNK1EANPEPLAP3RNPEPDNPEP | |
| SCHEMBL4047873 | 0.86 | BCHE (0.48) | CSNK1EANPEPLAP3RNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2319824-A3 | Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)amine | Ampac Fine Chemicals LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2319824-A2 | Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)amine | Ampac Fine Chemicals LLC (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20090203742-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SURLERAUX DOMINIQUE LOIS NESTO | 2009-08-13 | — | — | US | disclosed |
| US-20080200724-A1 | Sulphonamide chemical intermediate; aids inhibitor; crystal form ; N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)p-nitrobenzenesulfonamide | NPIL PHARMACEUTICALS (UK) LTD (GB) | 2008-08-21 | — | — | US | disclosed |
| EP-1893565-A1 | PROCESS AND COMPOUND | NPIL Pharmaceuticals (UK) Ltd (GB) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006131757-A1 | PROCESS AND COMPOUND | NPIL PHARMACEUTICALS (UK) LTD (GB) | 2006-12-14 | — | — | WO | disclosed |
| US-20050267156-A1 | Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. | 2005-12-01 | — | — | US | disclosed |
| EP-1545518-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004016619-A1 | BROADSPECTRUM SUBSTITUTED OXINDOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004014371-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200724-A1 | Sulphonamide chemical intermediate; aids inhibitor; crystal form ; N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)p-nitrobenzenesulfonamide | SPR, SULT1E1, SAMHD1 | CSNK1E 2292/4885ANPEP 68/4885ERAP2 3359/4885 |
| US-20090203742-A1 | BROADSPECTRUM 2-AMINO-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS2 | CSNK1E 1201/4885ANPEP 44/4885ERAP2 41/4885 |
| US-20050267156-A1 | Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors | PRSS1, SPINT2, TMPRSS2 | CSNK1E 1098/4885ANPEP 52/4885ERAP2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.